多发性骨髓瘤的基因组分类与个体化预后
研究纳入1933例新诊断多发性骨髓瘤(NDMM)患者,整合临床、基因组和治疗数据,鉴定出12个基因组分组,并构建个体化风险预测模型IRMMa。IRMMa的OS c-index为0.726,显著高于ISS(0.61)、修订版ISS(0.572)和R2-ISS(0.625),并在GMMG-HD6试验的256例患者中验证。不同治疗策略对12个基因组组的个体化风险有显著影响,可用于识别HDM-ASCT获益明显与获益有限的患者。
要点
- 基于基因组驱动因素鉴定出12个NDMM基因组分组。
- IRMMa模型OS c-index为0.726,高于ISS、R2-ISS等对照模型。
- 不同治疗策略对12个基因组组的个体化风险影响显著。
核心结论
- 整合临床、人口学、基因组和治疗数据,开发出首个个体化风险预测模型IRMMa,可为NDMM患者提供个体化治疗决策。
研究设计与样本
- 研究纳入1933例具有临床、基因组和治疗数据的新诊断多发性骨髓瘤患者,构建并验证个体化风险预测模型IRMMa。
- 采用多状态模型校正时间依赖性变量,包括大剂量美法仑后自体干细胞移植(HDM-ASCT)和维持治疗。
- 在GMMG-HD6临床试验(ClinicalTrials.gov标识符:NCT02495922)入组的256例患者中验证IRMMa的准确性和优越性。
主要发现
- IRMMa模型OS的c-index为0.726,显著高于ISS(0.61)、修订版ISS(0.572)和R2-ISS(0.625)。
- 模型准确性整合了20个基因组特征,包括1q21 gain/amp、del 1p、TP53 loss、NSD2易位、APOBEC突变特征和拷贝数特征(反映复杂结构变异染色体碎裂)。
- 在12个基因组组中,不同治疗策略对个体化患者风险有显著影响(即治疗方差),可用于识别HDM-ASCT特别有效与影响有限的患者。
临床怎么用
- 作者认为,IRMMa是首个个体化风险预测模型,可为NDMM患者提供个体化治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Outcomes for patients with newly diagnosed multiple myeloma (NDMM) are heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS: To decipher and predict the molecular and clinical heterogeneity of NDMM, we assembled a series of 1,933 patients with available clinical, genomic, and therapeutic data. RESULTS: Leveraging a comprehensive catalog of genomic drivers, we identified 12 groups, expanding on previous gene expression-based molecular classifications. To build a model predicting individualized risk in NDMM (IRMMa), we integrated clinical, genomic, and treatment variables. To correct for time-dependent variables, including high-dose melphalan followed by autologous stem-cell transplantation (HDM-ASCT), and maintenance therapy, a multi-state model was designed. The IRMMa model accuracy was significantly higher than all comparator prognostic models, with a c-index for OS of 0.726, compared with International Staging System (ISS; 0.61), revised-ISS (0.572), and R2-ISS (0.625). Integral to model accuracy was 20 genomic features, including 1q21 gain/amp, del 1p, TP53 loss, NSD2 translocations, APOBEC mutational signatures, and copy-number signatures (reflecting the complex structural variant chromothripsis). IRMMa accuracy and superiority compared with other prognostic models were validated on 256 patients enrolled in the GMMG-HD6 (ClinicalTrials.gov identifier: NCT02495922) clinical trial. Individualized patient risks were significantly affected across the 12 genomic groups by different treatment strategies (ie, treatment variance), which was used to identify patients for whom HDM-ASCT is particularly effective versus patients for whom the impact is limited. CONCLUSION: Integrating clinical, demographic, genomic, and therapeutic data, to our knowledge, we have developed the first individualized risk-prediction model enabling personally tailored therapeutic decisions for patients with NDMM.
引用
- Maura F, Rajanna AR, Ziccheddu B, et al. Genomic Classification and Individualized Prognosis in Multiple Myeloma. J Clin Oncol. 2024. PMID: 38194610. doi:10.1200/JCO.23.01277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。